| Literature DB >> 31513803 |
Eman Assrawi1, Camille Louvrier2, Clémence Lepelletier3, Sophie Georgin-Lavialle4, Jean-David Bouaziz3, Fawaz Awad5, Florence Moinet6, Philippe Moguelet7, Marie Dominique Vignon-Pennamen8, William Piterboth9, Claire Jumeau1, Laetitia Cobret1, Elma El Khouri1, Bruno Copin9, Philippe Duquesnoy1, Marie Legendre2, Gilles Grateau4, Sonia A Karabina1, Serge Amselem10, Irina Giurgea11.
Abstract
Chronic urticaria is a common skin disorder with heterogeneous causes. In the absence of physical triggers, chronic urticarial rash is called idiopathic or spontaneous. The objective of this study was to identify the molecular and cellular bases of a disease condition displayed by two unrelated patients aged over 60 years who presented for two decades with a chronic urticaria resistant to standard therapy that occurred in the context of systemic inflammation not triggered by cold. In both patients, a targeted sequencing approach using a next generation technology identified somatic mosaic mutations in NLRP3, a gene encoding a key inflammasome component. The study of several of both patients' cell types showed that, despite the late onset of the disease, NLRP3 mutations were not found to be restricted to myelomonocytic cells. Rather, the data obtained strongly suggested that the mutational event occurred very early, during embryonic development. As shown by functional studies, the identified mutations-an in-frame deletion and a recurrent NLRP3 missense mutation-have a gain-of-function effect on NLRP3-inflammasome activation. Consistently, a complete remission was obtained in both patients with anti-IL-1 receptor antagonists. This study unveils that in late-onset chronic urticaria, the search for autoinflammatory markers and somatic mosaic NLRP3 mutations may have important diagnostic and therapeutic consequences.Entities:
Year: 2019 PMID: 31513803 DOI: 10.1016/j.jid.2019.06.153
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551